{
    "clinical_study": {
        "@rank": "159777", 
        "acronym": "Compass", 
        "arm_group": [
            {
                "arm_group_label": "Test Group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Comparator Group", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to\n      Recombinant Human Follitropin Alfa for Injection for Ovulation Induction in Chinese females"
        }, 
        "brief_title": "Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Anovulation", 
        "condition_browse": {
            "mesh_term": "Anovulation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent form prior to screening evaluations\n\n          -  Chinese females between the ages of 20-39 years\n\n          -  Infertility for at least 1 year before screening\n\n          -  Women WHO type II anovulatory infertility with chronic anovulation (defined as\n             amenorrhoea (i.e., no menstrual bleeding for 6 months or more) or oligoamenorrhoea\n             (i.e., cycles of more than 35 days) ) with progestogen induced withdrawal bleeding or\n             spontaneous menstrual bleeding\n\n          -  Failure to conceive after at least one cycle of ovulation induction with clomiphene\n             citrate\n\n          -  Bilateral tubal patency documented by a hysterosalpingography or sonohysterography or\n             laparoscopy within 2 years prior to screening\n\n          -  Normal pelvis documented by a transvaginal ultrasound with respect to uterus,\n             Fallopian tubes and ovaries within 3 months prior to screening\n\n          -  Early follicular phase serum levels of FSH within normal limits (1-12 IU/L,) (results\n             obtained within 2 months prior to randomization)\n\n          -  LH (Luteinizing hormone), prolactin , E2 (estradiol), progesteron, total\n             testosterone, and TSH (thyrotropin) levels within normal limits for the clinical\n             laboratory\n\n          -  Male partner with a semen analysis obtained within 12 months prior to randomisation\n             and showing acceptable values for semen according to the local laboratory, or showing\n             more than 2.000.000 progressive motile sperm per mL after capacitation (in case of\n             IUI (intrauterine insemination))\n\n          -  BMI (Body mass index) is \u2265 18.5 and < 30 kg/m2\n\n        Exclusion Criteria:\n\n          -  Any known clinically significant systemic disease\n\n          -  Known past or current thrombophlebitis or thromboembolism including venous thrombosis\n             disease and active or recent arterial thrombosis disease\n\n          -  Any known endocrine or metabolic abnormalities which can compromise participation in\n             the trial with the exception of controlled thyroid function disease\n\n          -  Any known concomitant medications that would interfere with evaluation of study\n             medications. Specifically, any non-study hormonal therapy (except for thyroid\n             medication), anti-psychotics, anxiolytics, hypnotics and sedatives, and need for\n             continuous use of prostaglandin inhibitors (non-steroid anti- inflammatory drugs\n             (NSAIDs), including aspirin) at the time of study entry.\n\n          -  Known history of 12 or more unsuccessful (no pregnancy achieved) ovulation induction\n             cycles\n\n          -  Any known treatment with clomiphene citrate, metformin, gonadotropins or GnRH\n             analogues within one month prior to randomisation\n\n          -  Ovarian cysts with a mean diameter \u2265 15 mm that have persisted for more than one\n             cycle or ovarian endometrioma on ultrasound\n\n          -  Known at least one previous cycle experienced luteinized unruptured follicle syndrome\n\n          -  Known abnormal results of cervical examination of clinical significance obtained\n             within 1 years prior to screening\n\n          -  Abnormal vaginal bleeding of undetermined origin\n\n          -  Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus\n\n          -  Known malformations of the sexual organs incompatible with pregnancy\n\n          -  Known current or past (last 12 months) abuse of alcohol or drugs\n\n          -  Known history of chemotherapy (except for gestational conditions) or radiotherapy\n\n          -  Finding of any clinically relevant abnormal laboratory value\n\n          -  Use of any non registered investigational drugs during 3 months before screening or\n             previous participation in the study\n\n          -  Pregnancy, lactation or contraindication to pregnancy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "39 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01923194", 
            "org_study_id": "000055"
        }, 
        "intervention": [
            {
                "arm_group_label": "Test Group", 
                "description": "for Injection", 
                "intervention_name": "Highly Purified Urofollitropin", 
                "intervention_type": "Drug", 
                "other_name": "Bravelle\u00ae"
            }, 
            {
                "arm_group_label": "Comparator Group", 
                "description": "for Injection", 
                "intervention_name": "Recombinant Human Follitropin Alfa", 
                "intervention_type": "Drug", 
                "other_name": "Gonal-F\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Follicle Stimulating Hormone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Peking Union Medical College Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Peking University People's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Peking University First Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Chinese PLA General Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "Sun Yat-sen Memorial Hospital Sun Yat-sen University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "The Third Affiliated Hospital of Guangzhou Medical University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei"
                    }, 
                    "name": "Tongji Hospital Tongji Medical College of HUST Tongji Medical College Huazhong University of Science & Technology"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu"
                    }, 
                    "name": "The First Affiliated Hospital with Nanjing Medical University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "state": "Liaoning"
                    }, 
                    "name": "ShengJing Hospital of China Medical University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan"
                    }, 
                    "name": "Sichuan Provincial People's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin"
                    }, 
                    "name": "Tianjin Medical University General Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection for Ovulation Induction Using a Low-dose, Step-up Protocol in Chinese Females With WHO Group II Anovulatory Infertility Failing to Conceive on Clomiphene Citrate", 
        "overall_contact": {
            "email": "DK0-Disclosure@ferring.com", 
            "last_name": "Clinical Development Support"
        }, 
        "overall_official": {
            "affiliation": "Ferring Pharmaceuticals", 
            "last_name": "Clinical Development Support", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The ovulation rate defined as the percentage of subjects who present ovulation", 
            "safety_issue": "No", 
            "time_frame": "From 6 days up to 7 weeks post hCG (human chorionic gonadotropin) administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01923194"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The positive serum progesterone rate", 
                "safety_issue": "No", 
                "time_frame": "6~9 days post hCG administration"
            }, 
            {
                "measure": "The positive serum \u03b2-hCG/hCG rate", 
                "safety_issue": "No", 
                "time_frame": "18~22 days post hCG administration"
            }, 
            {
                "description": "Regardless of fetal heart beat", 
                "measure": "The clinical pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "6~7 weeks post hCG administration"
            }, 
            {
                "description": "With fetal heart beat", 
                "measure": "The clinical pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "6~7 weeks post hCG administration"
            }, 
            {
                "measure": "The ongoing pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "11~12 weeks post hCG administration"
            }, 
            {
                "measure": "The follicular development", 
                "safety_issue": "No", 
                "time_frame": "On the day of hCG administration"
            }, 
            {
                "measure": "Endometrial thickness", 
                "safety_issue": "No", 
                "time_frame": "On the day of hCG administration"
            }, 
            {
                "measure": "Total FSH (Follicle-stimulating hormone) dose administered", 
                "safety_issue": "No", 
                "time_frame": "On the day of hCG administration"
            }, 
            {
                "measure": "Number of FSH treatment days", 
                "safety_issue": "No", 
                "time_frame": "On the day of hCG administration"
            }, 
            {
                "measure": "Frequency and severity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Expected maximum of 6 months"
            }, 
            {
                "measure": "Frequency and severity of injection site reactions", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 up to Day 28 of the ovarian stimulation period"
            }, 
            {
                "measure": "Serum estradiol (E2) levels", 
                "safety_issue": "No", 
                "time_frame": "On the day of hCG administration"
            }
        ], 
        "source": "Ferring Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}